2-oxothiazole compounds and method of using same for chronic inflammatory disorders
AssigneeAvexxin AS
InventorsGeorge Kokotos, Berit Johansen, Victoria Magrioti, Michael Tsakos
Life of this patent
Estimating the term…
Loading patent…
AssigneeAvexxin AS
InventorsGeorge Kokotos, Berit Johansen, Victoria Magrioti, Michael Tsakos
Estimating the term…
The invention provides compounds of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3); each R5 is defined as for R1; V1 is a covalent bond, —O—, or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R4 is H, halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkylh, haloC1-6alkyl, a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group, said C1-20alkyl or C2-20oalkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; with the proviso that the group V1M1R4 as a whole provides at least 4 backbone atoms from the C(R3) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.
A method of treating a chronic inflammatory disorder mediated by phospholipase enzyme cPLA2 activity comprising administering to a patient in need thereof an effective amount of a compound of the following formula:
A method of treating a chronic inflammatory disorder selected from the group consisting of glomerulonephritis, rheumatoid arthritis and psoriasis, comprising administering to a patient in need thereof an effective amount of a compound of the following formula:
A method of treating a chronic inflammatory disorder mediated by phospholipase enzyme cPLA2 activity comprising administering to a patient in need thereof an effective amount of a compound of the following formula:
A method of treating a chronic inflammatory disorder selected from the group consisting of glomerulonephritis, rheumatoid arthritis and psoriasis, comprising administering to a patient in need thereof an effective amount of a compound of the following formula:
Dependencies are inferred from the claim text.